secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2025-04-07T23:59:59+00:00
Accession:  0001437749-25-011178
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed reports positive Phase 2b extension data for neflamapimod in DLB
-------------------------------------------------------------------------

- Neflamapimod slowed clinical progression on CDR-SB vs old capsules (p<0.001) and vs placebo (p=0.003) over 16 weeks.
- Mean CDR-SB improvement of 0.73 points with new capsules vs old; 40% relative reduction in clinically meaningful worsening.
- Falls incidence reduced to 4% with new capsules vs 15.2% with old (p=0.025) in patients without AD co-pathology.
- Improvement also seen on ADCS-CGIC (p=0.035 vs old capsules) and cognitive/fluctuation endpoints.
- Company expects to complete full 32-week extension and engage FDA for Phase 3 plans later in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774925011178/0001437749-25-011178-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774925011178/crvo20250407_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-011178

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer